(New York Post) Sure Bill Ackman gets a lot of ink and a lot of criticism as one of the largest investors behind the crisis-ridden Valeant Pharmaceuticals. But another activist investment firm with a much larger role in Valeant’s activities has largely gone unquestioned: ValueAct, a San Francisco based investor that also has a large stake and board seat on Microsoft….
ValueAct Pays a Price for Its Supporting Role at Valeant
This entry was posted in Syndicated. Bookmark the permalink.
